Testing a stimulation device for arm weakness after stroke or brain injury
Compares the SSMD device with standard electrical stimulation for arm recovery in adults.
Plain-language title generated from the registry record
Registry title: Safety and Effectiveness of Spatial StimelMD (SSMD) in Subjects With Upper Limb Neuromotor Impairments
Key facts
- Where
- Haifa, IsraelSee the site
Where in Israel
- Bnai Zion Medical CenterHaifa, IsraelTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Motion Informatics LTD
- Trial code
- NCT07404761
- Record updated
- 11 February 2026
- Original description
This is a multicenter, randomized, controlled clinical study evaluating the safety and effectiveness of the Spatial StimelMD (SSMD) device for upper-limb neuromotor rehabilitation in adults with impairment following stroke or traumatic brain injury (TBI).Read full original descriptionShow less
A Multicenter, Randomized, Controlled Study to Evaluate the Efficacy and Safety of the SSMD in Neuromotor Rehabilitation
This is a multicenter, randomized, controlled clinical study evaluating the safety and effectiveness of the Spatial StimelMD (SSMD) device for upper-limb neuromotor rehabilitation in adults with impairment following stroke or traumatic brain injury (TBI).
Participants will be randomized to receive either SSMD therapy plus standard rehabilitation care or standard functional electrical stimulation (FES) plus standard care. Subjects will complete approximately 25 supervised treatment sessions over 5-6 weeks, with assessments at baseline, mid-treatment, post-treatment (primary endpoint), and a 1-month follow-up.
The primary effectiveness endpoint is improvement in upper-limb motor function measured by the Fugl-Meyer Upper Extremity (FMA-UE) assessment. Secondary outcomes include movement metrics, EMG signal strength, functional independence, usability measures, and adverse event monitoring.
The study plans to enroll approximately 150 subjects to achieve 126 completers, across 2-6 clinical sites.
Inclusion: Adults aged 18-80 years; Clinically confirmed diagnosis of stroke or TBI within the past 12 months; Presence of moderate to severe neuromotor impairment in at least one limb, as evidenced by medical evaluation and a score <35 on the Fugl-Meyer Upper Extremity motor subscale (FMA-UE); Capacity and willingness to provide informed consent, indicating understanding of the study purpose, procedures, and potential risks and benefits; Subject is able to adhere to the study schedule and cognitively capable to perform the treatment; Stable medical condition without ongoing acute complications that could interfere with participation.
Exclusion: Presence of contraindications to electrical stimulation (ES), including implanted electronic medical devices (e.g., pacemakers, insulin pumps) or conditions that may be exacerbated by electrical stimulation (e.g., uncontrolled epilepsy); Individuals with medical conditions, which are prone to seizures or motion sensitivity, at the investigator's discretion; Individuals with acute physical conditions or injuries that could interfere with the proper placement of the electrodes or safe use of the device; Severe cognitive impairment that precludes the ability to provide informed consent or reliably adhere to the study protocol, as determined by cognitive screening and clinical judgment; Individuals with light sensitivity, as the AR component may involve visual stimuli that could cause discomfort or adverse reactions in these patients; Presence of spinal shock or unresolved acute spinal cord dysfunction, characterized by complete loss of reflexes, flaccid paralysis, or autonomic instability; Current participation in other clinical trials that could confound the study results; Women who are pregnant, nursing, or who plan to become pregnant while in the trial.